|
---|
As Of | Filer | Filing¹ | For·On·As | Docs:Size | Issuer | | Filing Agent | | | | | | | | | |
---|
|
---|
5/15/24 Adaptimmune Therapeutics plc 10-Q 3/31/24 78:6.2M Toppan Merrill Bridge/FA
5/15/24 Adaptimmune Therapeutics plc 8-K:2,9 5/15/24 11:451K Toppan Merrill Bridge/FA
5/15/24 Adaptimmune Therapeutics plc 8-K:1,2,7,9 5/14/24 11:190K Toppan Merrill Bridge/FA
5/14/24 Adaptimmune Therapeutics plc 8-K:5 5/14/24 10:218K Toppan Merrill/FA
4/22/24 Adaptimmune Therapeutics plc ARS 12/31/23 1:2.6M Toppan Merrill/FA
4/12/24 Adaptimmune Therapeutics plc 8-K:1,9 4/10/24 11:179K Toppan Merrill Bridge/FA
4/11/24 Adaptimmune Therapeutics plc DEF 14A 5/14/24 11:6M Toppan Merrill/FA
4/2/24‡ New Enterprise Assocs 14, L.P. SC 13D/A 4/2/24 1:385K Adaptimmune Therapeutics plc Go2 EDGAR SOLUTIONS… /FA
Anthony A. Florence, Jr.³
Forest Baskett³
Mohamad H. Makhzoumi³
Nea 14 GP, Ltd.³
Nea 16 GP, LLC³
Nea Partners 14, L.P.³
NEA Partners 16, L.P.³
New Enterprise Associates 16, L.P.³
Patrick J. Kerins³
Scott D. Sandell³
4/1/24 Adaptimmune Therapeutics plc PRE 14A 5/14/24 12:6M Toppan Merrill/FA
3/26/24 EcoR1 Capital, LLC 3 10% Owner² 1:5K Adaptimmune Therapeutics plc Shartsis Friese LLP
3/26/24 EcoR1 Capital, LLC SC 13G/A 1:49K Adaptimmune Therapeutics plc Shartsis Friese LLP
3/18/24 Piccina Cintia 4 Officer² 1:7K Adaptimmune Therapeutics plc Toppan Merrill/FA
3/6/24 Adaptimmune Therapeutics plc 10-K 12/31/23 131:16M Toppan Merrill Bridge/FA
3/6/24 Adaptimmune Therapeutics plc 8-K:2,9 3/6/24 11:494K Toppan Merrill Bridge/FA
2/27/24 Adaptimmune Therapeutics plc 8-K:5,9 2/26/24 12:335K Toppan Merrill Bridge/FA
2/16/24 Adaptimmune Therapeutics plc 8-K:3 2/16/24 10:144K Toppan Merrill Bridge/FA
2/14/24 Long Focus Capital Mgmt, LLC SC 13G/A 2:139K Adaptimmune Therapeutics plc Borer Fin’l Comms, Inc.
A. Glenn Helmers³
Condagua, LLC³
John B. Helmers³
Long Focus Capital Management, LLC³
Long Focus Capital Master, Ltd.³
2/14/24 Baker Bros. Advisors LP SC 13G/A 1:87K Adaptimmune Therapeutics plc Toppan Merrill/FA
Baker Bros. Advisors (GP) LLC³
Felix J. Baker³
Julian C. Baker³
1/31/24 Adaptimmune Therapeutics plc 8-K:8,9 1/31/24 11:188K Toppan Merrill Bridge/FA
1/30/24 EcoR1 Capital, LLC SC 13G 1:49K Adaptimmune Therapeutics plc Shartsis Friese LLP
____________ | ‡ | A non-Insider-Ownership Filing that was accepted after the SEC “closed” at 5:30:00pm ET. The legal “Filed As Of” date may be the next, or another, day. | ¹ | Filing/Form Types: | | 3 | Initial Statement of Beneficial Ownership of Securities by an Insider — Form 3 { The Filer is an Insider² of the Issuer }. | | 4 | Statement of Changes in Beneficial Ownership of Securities by an Insider — Form 4 { The Filer is an Insider² of the Issuer }. | | 8-K | Current Report — Form 8-K { Item 1: Business & Operations; 2: Financial Info; 3: Securities & Trading; 4: Accountants & Accounting; 5: Governance & Management; 6: Asset-Backed Securities; 7: Disclosures; 8: Events; 9: Financials }. | | 10-K | Annual Report — Form 10-K. | | 10-Q | Quarterly Report — Form 10-Q. | | ARS | Annual Report to Security Holders. | | DEF 14A | Definitive Proxy Statement — Schedule 14A. | | PRE 14A | Preliminary Proxy Statement — Schedule 14A. | | SC 13D | Statement of Acquisition of Beneficial Ownership by an “Active” Investor — Schedule 13D. | | SC 13G | Statement of Acquisition of Beneficial Ownership by a “Passive” Investor — Schedule 13G. | | /A | Amendment to, or Amended version of, a previous Filing of this Type. | ² | Insider: The Filer is a Director, Officer, 10% Owner and/or Other “insider” of the Issuer. | ³ | Group Member: A Registrant or non-Registrant party to this Filing made by a Group. |
|